Overview

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study
Phase:
Phase 3
Details
Lead Sponsor:
Fadoi Foundation, Italy
Collaborator:
University of Perugia, Italy
Treatments:
Apixaban
Dalteparin
Heparin, Low-Molecular-Weight
Tinzaparin